X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (123) 123
oncology (89) 89
index medicus (76) 76
melanoma (68) 68
female (67) 67
male (56) 56
middle aged (56) 56
melanoma - pathology (49) 49
melanoma - drug therapy (45) 45
article (40) 40
adult (38) 38
cancer (36) 36
aged (33) 33
skin neoplasms - pathology (27) 27
melanoma - genetics (24) 24
animals (23) 23
malignant-melanoma (22) 22
survival (20) 20
mice (19) 19
prognosis (19) 19
immunotherapy (18) 18
metastases (18) 18
metastatic melanoma (18) 18
mutation (18) 18
neoplasm staging (17) 17
proto-oncogene proteins b-raf - genetics (17) 17
research (16) 16
skin neoplasms - drug therapy (16) 16
braf (15) 15
cell biology (15) 15
cell line, tumor (15) 15
patients (15) 15
therapy (15) 15
aged, 80 and over (14) 14
antineoplastic agents - therapeutic use (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
melanoma - immunology (14) 14
metastasis (14) 14
tumors (14) 14
melanoma - secondary (13) 13
treatment outcome (13) 13
biopsy (12) 12
cutaneous melanoma (12) 12
dermatology (12) 12
immunology (12) 12
melanoma - mortality (12) 12
neoplasm metastasis (12) 12
proto-oncogene proteins b-raf - antagonists & inhibitors (12) 12
chemotherapy (11) 11
expression (11) 11
risk (11) 11
vemurafenib (11) 11
care and treatment (10) 10
follow-up studies (10) 10
lymphocytes (10) 10
melanoma - metabolism (10) 10
melanoma - therapy (10) 10
skin neoplasms - genetics (10) 10
surgery (10) 10
acquired-resistance (9) 9
cells (9) 9
ipilimumab (9) 9
medicine & public health (9) 9
protein kinase inhibitors - pharmacology (9) 9
skin neoplasms - mortality (9) 9
trial (9) 9
xenograft model antitumor assays (9) 9
abridged index medicus (8) 8
antineoplastic agents - adverse effects (8) 8
clinical trials (8) 8
combination (8) 8
combined modality therapy (8) 8
disease progression (8) 8
mutations (8) 8
neoplasms - drug therapy (8) 8
neoplasms - therapy (8) 8
resistance (8) 8
risk factors (8) 8
antineoplastic agents - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
biology (7) 7
breast-cancer (7) 7
drug therapy (7) 7
genetic aspects (7) 7
indoles - pharmacology (7) 7
lung-cancer (7) 7
lymphatic metastasis (7) 7
medicine, general & internal (7) 7
mek inhibition (7) 7
melanoma - surgery (7) 7
multidisciplinary sciences (7) 7
neoplasms (7) 7
pathway (7) 7
phenotype (7) 7
skin cancer (7) 7
skin neoplasms - therapy (7) 7
sulfonamides - pharmacology (7) 7
united states (7) 7
adolescent (6) 6
analysis (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of surgical oncology, ISSN 1068-9265, 07/2019
Immune checkpoint and BRAF-targeted inhibitors have demonstrated significant survival benefits for advanced melanoma patients within the context of clinical... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1888 - 1890
Every year in the United States, approximately 87,000 patients receive the diagnosis of melanoma. Although most of these patients are cured with simple... 
TRIAL | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | STAGE-III MELANOMA | MEK INHIBITION | BRAF INHIBITORS | IPILIMUMAB | Interferon-alpha | Humans | Melanoma | Skin Neoplasms | Combined Modality Therapy | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Immunotherapy | Clinical trials | Interferon | FDA approval | Mutation | Cancer therapies | Drug dosages
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 373 - 377
Journal Article
Nature, ISSN 0028-0836, 05/2017, Volume 545, Issue 7652, pp. 60 - 65
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical... 
CRITERIA | MELANOMA | PEMBROLIZUMAB | IMMUNE CHECKPOINT BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | BRAF INHIBITORS | CHRONIC VIRAL-INFECTION | CANCER-THERAPY | IPILIMUMAB | EXHAUSTION | CD8-Positive T-Lymphocytes - cytology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - blood supply | Humans | Ki-67 Antigen - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Melanoma - pathology | Phenotype | Antibodies, Monoclonal, Humanized - administration & dosage | Ki-67 Antigen - immunology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Melanoma - immunology | Melanoma - drug therapy | CD8-Positive T-Lymphocytes - metabolism | Female | Programmed Cell Death 1 Receptor - immunology | Antibodies, Monoclonal, Humanized - immunology | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Tumor Burden - immunology | Oncology, Experimental | Melanoma | Physiological aspects | Research | T cells | Tumors | Apoptosis | Cancer | Profiling | PD-1 protein | CD8 antigen | Medical services | Clinical trials | Lymphocytes T | Blood | Metastases | Immunology | Lymphocytes | Immunotherapy | Peripheral blood | Pretreatment | Medical research | Immunoglobulins | T cell receptors | Pharmacology | Patients | Pathology | Cell death | PD-L1 protein | Infiltration
Journal Article
Cancer Cell, ISSN 1535-6108, 09/2017, Volume 32, Issue 3, p. 377
How tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic constrains within the tumor microenvironment (TME) and to what degree this affects their... 
Antigens | Care and treatment | Immunotherapy | Melanoma | Physiological aspects | Development and progression | Drug therapy | T cells | Fatty acids | Tumors | Cancer | Glucose | Dextrose
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2014, Volume 124, Issue 3, pp. 1406 - 1417
Journal Article
Journal of Cutaneous Pathology, ISSN 0303-6987, 09/2016, Volume 43, Issue 9, pp. 776 - 780
Journal Article
Nature, ISSN 0028-0836, 08/2018, Volume 560, Issue 7718, pp. 382 - 386
Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1... 
CELLS | MELANOMA | PEMBROLIZUMAB | EXTRACELLULAR VESICLES | MULTIDISCIPLINARY SCIENCES | RESISTANCE | INDUCE APOPTOSIS | EXPRESSION | T-LYMPHOCYTES | NECK-CANCER | CHECKPOINT BLOCKADE | Exosomes - metabolism | Tumor Escape - drug effects | Prognosis | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Case-Control Studies | Neoplasm Metastasis | Immune Tolerance - immunology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Immune Tolerance - drug effects | Tumor Escape - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - pathology | B7-H1 Antigen - immunology | Disease Progression | Antineoplastic Agents, Immunological - pharmacology | Xenograft Model Antitumor Assays | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - blood | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - immunology | Mice, Nude | CD8-Positive T-Lymphocytes - drug effects | Interferon-gamma - immunology | Melanoma - drug therapy | Cell Line, Tumor | Mice | Programmed Cell Death 1 Receptor - immunology | CD8-Positive T-Lymphocytes - immunology | Interferon-gamma - blood | Viral antibodies | Immunosuppression | Antibodies | Metastasis | Research | T cells | Properties | Biological response modifiers | Therapy | PD-1 protein | CD8 antigen | Lymphocytes T | Exosomes | Cancer therapies | Metastases | Skin cancer | Proteins | Vesicles | Lymphocytes | Immunotherapy | Immune system | Immunoglobulins | Melanoma | Immunosurveillance | T cell receptors | Patients | Immune checkpoint | Microscopy | PD-L1 protein | Ligands | Interferon | Head & neck cancer | Tumors | Apoptosis
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2014, Volume 124, Issue 3, pp. 1406 - 1406
Melanomas that result from mutations in the gene encoding BRAF often become resistant to BRAF inhibition (BRAFi), with multiple mechanisms contributing to... 
Journal Article
Journal Article